Investigation Report on China Edaravone Market, 2010-2019

Cerebrovascular disease is one of the three principal diseases that can cause people to death. Acute cerebral infarction which occupies 70% of cerebrovascular disease has…
Reference: 1506209
Price: $2,000.00
Tax included

General

Publisher:
CRI
Geography Covered
China
Publication Date
6/11/2015
Pages
30
Version:
2010
Charts:
20
Language
  • English
  • Chinese
Format
License

Description

Cerebrovascular disease is one of the three principal diseases that can cause people to death. Acute cerebral infarction which occupies 70% of cerebrovascular disease has a disability rate of 50%-70% and a recurrence rate of 40%. And one thing to be noted is that the more relapses people have, the higher the mortality and disability.
Acute cerebral infarction, one of the serious threats to old people’s health, features sudden onset, complex pathogenesis and “three high and one low”: high morbidity, high mortality, high fatality and low cure rate.
Edaravone injection, a life-saving drug for the treatment of acute cerebral infarction, is the only free radical scavenger in the world with a clear mechanism and target of acute cerebral infarction. Ever since its debut in Japan in 2002, its sales in the first 13 months has surpassed JPY 40 billion.
Simcere is China’s first and world’s second manufacturer of edaravone injection. Its new product “Bi Cun” is priced at 1/33 of the price of similar products in Japan. In 2007, “Bi Cun” spread over China with a market share of 74.62%. According to CRI’s statistics, edaravone develops fast after entering China, annual sales value rising from less than CNY 50 million in 2005 to CNY 629 million in 2014 and CAGR reaching up to 34.3% during the period of 2005-2015. Currently, local manufacturers of edaravone are as follows: Simcere, Jilin Boda Pharmaceutical Co., Ltd, Jilin Province Huinan Changlong Biopharmacy Co., Ltd and Kunming Jida Pharmaceutical Co., Ltd, among which Simcere has the largest market share of 39% with sales value reaching up to CNY 246 million in 2014.
With the ageing population, the incidence of acute cerebral infarction in China will keep increasing, thus promoting the growth of edaravone market.

Readers can get at least the following information from this report:
-market size of edaravone in China
-market share of manufacturers of edaravone in China
-price of edaravone in Chinese market
-major manufacturers of edaravone in Chinese market
-market outlook of edaravone in China

The author suggests the following groups of people purchase this report:
-manufacturers of cerebrovascular drugs
-investors/ research institutions interested in Chinese medicine market
-any interest in the Chinese medicine market, please contact CRI for customized survey service
Table of Contents

1 Related Concepts of Edaravone
1.1 Indication
1.2 Sales Status in Global Market

2 Market Profile of Edaravone in China
2.1 Patent and Approval Status of Edaravone in China
2.2 Major Manufacturers
2.3 Market Size

3 Survey on Sales Status of Edaravone in China, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions

4 Survey on Market Share of Major Manufacturers of Edaravone in China, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume

5 Survey on Dosage Forms of Edaravone in China, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume

6 Reference Price of Edaravone in Chinese Hospitals in 2014
6.1 Kunming Jida Pharmaceutical Co., Ltd
6.2 Nanjing Simcere Dongyuan Pharmaceutical Co.,Ltd.
6.3 Jilin Boda Pharmaceutical Co., Ltd (Trade Name: Yi Da Sheng)
6.4 Jilin Province Huinan Changlong Biopharmacy Co., Ltd (Trade Name: Qing Tong)
6.5 China National Medicines Guorui Pharmaceutical Co., Ltd
6.6 Science & Technology General Company Hebei Medical University (Trade Name: Kai Da Fu Xin)
6.7 Fujian Tianquan Pharmaceutical Co., Ltd
6.8 Shaanxi Jianmin Pharmaceutical Co., Ltd (Trade Name: Bai Yi Da)

7 Major Manufacturers of Edaravone in Chinese Market, 2010-2014
7.1 Jilin Boda Pharmaceutical Co., Ltd
7.2 Jilin Province Huinan Changlong Biopharmacy Co., Ltd
7.3 Nanjing Simcere Dongyuan Pharmaceutical Co.,Ltd.
7.4 Kunming Jida Pharmaceutical Co., Ltd
7.5 China National Medicines Guorui Pharmaceutical Co., Ltd

8 Market Outlook of Edaravone in China, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape

Selected Charts

Chart Approval Information of Edaravone in China
Chart Sales Status of Edaravone in China, 2010-2014
Chart Sales Value of Edaravone in China, 2010-2014
Chart Sales Value of Edaravone in Some Regions in China, 2010-2014
Chart Sales Volume of Edaravone in China, 2010-2014
Chart Market Share of TOP5 Manufacturers of Edaravone for Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Edaravone Made by Simcere in China, 2010-2014
Chart Sales Value and Market Share of Edaravone Made by Jilin Boda in China, 2010-2014
Chart Sales Value and Market Share of Edaravone Made by Kunming Jida in China, 2010-2014
Chart Sales Value and Market Share of Edaravone Made by Huinan Changlong in China, 2010-2014
Chart Sales Value and Market Share of Edaravone Made by Guorui in China, 2010-2014
Chart Sales Value and Market Share of Edaravone Injection in China, 2010-2014
Chart Price of Edaravone Made by Kunming Jida Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Chart Price of Edaravone Made by Simcere in Some Chinese Cities in 2014
Chart Price of Edaravone Made by Jilin Boda Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Chart Price of Edaravone Made by Jilin Province Huinan Changlong Biopharmacy Co., Ltd in Some Chinese Cities in 2014
Chart Price of Edaravone Made by China National Medicines Guorui Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Scroll